Pfizer appoints Dr Yvonne Greenstreet to specialty care business

pharmafile | February 3, 2011 | Appointment | Research and Development Dr Yvonne Greenstreet, Pfizer, appointment, specialty care 

Dr Yvonne Greenstreet has joined Pfizer to head up medicines development for its Specialty Care business unit.

She moves to the company after 18 years with GlaxoSmithKline, where she was most recently chief of strategy, research and development.

At GSK she was responsible for leading the development of small molecules and biologics, and previously oversaw clinical development and medical affairs for the company’s European business.

Advertisement

“Yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry,” said Geno Germano, president and general manager of Pfizer’s Specialty Care Business Unit.

“Her experience in delivering medicines in challenging markets is noteworthy, and she will play an important role in advancing Specialty Care’s commitment to the eradication, remission and relief of serious diseases.”

Before joining GSK, Yvonne practiced medicine in the NHS, working in a number of leading teaching hospitals in London.

At Pfizer she takes over from Dr Michael Berelowitz, who retires after a 14-year career at the company, and she will report directly to Germano and join his leadership team.

Related Content

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

The Gateway to Local Adoption Series

Latest content